Table 2

Toxicities

Patients (grade-number of patients)
Taxol (mg/m2)Patients/cyclesHBaPLTANCG-CSF administrationMucositisDiarrheaN/VNeuro
25012/3112 (IV-1, III-5, II-6)5 (IV-2, III-1, II-2)8 (IV-1, III-4, II-1, I-2)127 (IV-1, III-3, II-3)9 (III-2, II-4, I-3)7 (II-5, I-2)6 (II-3, I-3)
2256/20 4 (III-2, II-2)2 (IV-1, III-1)3 (IV-1, III-1, II-1, I-2)35 (III-1, II-2, I-2)3 (I-3)3 (II-2, I-1)2 (II-1, I-1)
2007/23 4 (IV-2, III-2)5 (IV-2, II-2, I-1)7 (IV-2, III-3, I-2)27 (III-2, II-5)6 (II-6)7 (III-1, II-2, I-4)2 (II-1, I-1)
1707/24 2 (III-1, II-1)3 (IV-1, III-1, I-1)6 (IV-2, III-1, II-3)25 (IV-2, II-2, I-1)2 (II-1, I-1)7 (III-1, II-4, I-2)2 (II-1, I-2)
1357/22 5 (IV-1, III-2, II-2)6 (IV-2, III-1, II-1, I-2)7 (IV-2, III-3, I-1)24 (IV-1, III-1, I-2)4 (III-1, II-2, I-1)6 (II-3, I-3)1 (I-1)
1003/9 3 (III-1, II-2)2 (I-2)3 (III-1, II-2)02 (II-1, I-1)1 (I-1)3 (II-1, I-2)None
  • a HB, hemoglobin; PLT, platelets; N/V, nausea/vomiting; Neuro, peripheral neuropathy.